Promising heart disease drug pelacarsen fails major clinical trial unexpectedly
An experimental drug called pelacarsen failed to prevent heart attacks and strokes despite successfully lowering lipoprotein(a), a genetic heart risk factor, in a major clinical trial. The seven-year study involving over eight thousand patients showed pelacarsen reduced Lp(a) levels by 78 percent, but patients taking the drug had virtually the same risk of cardiovascular events as those receiving a placebo. About 12 percent of patients in each group experienced heart attacks, strokes, or cardiovascular deaths. The failure surprised researchers worldwide because high Lp(a) has long been associated with increased heart disease risk. Doctors were hoping this drug would become a major advance in heart attack prevention. Other companies including Amgen and Eli Lilly are testing similar Lp(a)-lowering drugs, with results expected in coming years. Experts continue studying why lowering the particle did not translate to patient benefit.
Key facts
- Novartis pelacarsen drug reduced lipoprotein(a) by 78 percent in clinical trial
- Trial involved 8,323 patients with existing cardiovascular disease across 42 countries
- Seven-year trial showed 12.3 percent major cardiovascular events in pelacarsen group versus 12.1 percent in placebo group
- Study was called Lp(a) HORIZON and led by Dr. Steven Nissen of Cleveland Clinic
- Drug was presented at American Heart Association annual conference November 7, 2026, and published in New England Journal of Medicine
- Amgen and Eli Lilly are developing alternative Lp(a)-lowering drugs in clinical trials
Limits of this briefing
This story appears primarily in medical, scientific, and centrist news outlets. No distinctly partisan left-leaning or right-leaning coverage of this clinical trial failure was found, which is typical for apolitical medical science news. Some sources speculate on why the trial failed, but these remain working hypotheses rather than confirmed explanations.
Sources
- NBC News: Cholesterol drug pelacarsen fails to prevent heart attacks in major trial Centre
- CNN: Pelacarsen, a promising drug for an inherited heart risk, flops, stunning doctors Centre
- NPR: An experimental drug that lowers lipoprotein(a) fails to help patients Centre
- CNBC: Novartis pelacarsen Lp(a) trial fails, raising doubts for Amgen, Lilly Centre
- Cleveland Clinic Newsroom: Cleveland Clinic Trial Shows Novel Lipoprotein(a) Drug Did Not Reduce Major Cardiovascular Events After Nearly 5 Years Centre